This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Well Characterized Biologics & Biological Assays
Well Characterized Biologics & Biological Assays is now part of BioProcess International
September 23-26, 2024Hynes Convention Center in Boston, USA

Eric Bishop
Vice President of Research & Development at Cygnus Technologies


Eric Bishop is the Vice President for Research and Development at Cygnus Technologies. Eric leads the research and development team and is responsible for new product development and custom development services. Eric has 25 years of experience in HCP analytics. Eric joined Cygnus Technologies in 2010, bringing a background in R&D for several biopharmaceutical companies. Prior to joining Cygnus, Eric worked for AstraZeneca, formerly MedImmune, from 2002-2010. During his time there he had multiple roles from HCP assay development and tech transfer to being Analytical Representative on CMC teams guiding projects from IND to BLA submissions as well as Head of New Technology Development group. Prior to AstraZeneca, he was at CropTech Development from 1998-2002, where he was involved in characterization of recombinant proteins produced in plants.

Agenda Sessions

  • Advanced Orthogonal Methods to Fully Characterize Process HCPs